Innate Pharma (IPHA) Competitors $2.14 +0.02 (+1.18%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPHA vs. IMNM, RCKT, AVBP, DAWN, TRVI, IMTX, SION, EOLS, VIR, and REPLShould you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Immunome (IMNM), Rocket Pharmaceuticals (RCKT), ArriVent BioPharma (AVBP), Day One Biopharmaceuticals (DAWN), Trevi Therapeutics (TRVI), Immatics (IMTX), Sionna Therapeutics (SION), Evolus (EOLS), Vir Biotechnology (VIR), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry. Innate Pharma vs. Immunome Rocket Pharmaceuticals ArriVent BioPharma Day One Biopharmaceuticals Trevi Therapeutics Immatics Sionna Therapeutics Evolus Vir Biotechnology Replimune Group Immunome (NASDAQ:IMNM) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, dividends, profitability, earnings, media sentiment, valuation and risk. Do analysts recommend IMNM or IPHA? Immunome presently has a consensus target price of $23.33, indicating a potential upside of 194.61%. Innate Pharma has a consensus target price of $11.00, indicating a potential upside of 414.02%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Innate Pharma is more favorable than Immunome.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the MarketBeat Community favor IMNM or IPHA? Innate Pharma received 9 more outperform votes than Immunome when rated by MarketBeat users. However, 78.00% of users gave Immunome an outperform vote while only 60.00% of users gave Innate Pharma an outperform vote. CompanyUnderperformOutperformImmunomeOutperform Votes3978.00% Underperform Votes1122.00% Innate PharmaOutperform Votes4860.00% Underperform Votes3240.00% Which has more volatility & risk, IMNM or IPHA? Immunome has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Does the media refer more to IMNM or IPHA? In the previous week, Immunome had 7 more articles in the media than Innate Pharma. MarketBeat recorded 9 mentions for Immunome and 2 mentions for Innate Pharma. Immunome's average media sentiment score of 0.91 beat Innate Pharma's score of 0.00 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, IMNM or IPHA? Innate Pharma has higher revenue and earnings than Immunome. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunome$10.94M63.00-$106.81M-$3.18-2.49Innate Pharma$12.62M14.21-$8.19MN/AN/A Do institutionals and insiders hold more shares of IMNM or IPHA? 44.6% of Immunome shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 8.6% of Immunome shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is IMNM or IPHA more profitable? Innate Pharma has a net margin of 0.00% compared to Immunome's net margin of -3,014.59%. Innate Pharma's return on equity of 0.00% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets Immunome-3,014.59% -48.63% -41.62% Innate Pharma N/A N/A N/A SummaryInnate Pharma beats Immunome on 10 of the 17 factors compared between the two stocks. Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPHA vs. The Competition Export to ExcelMetricInnate PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$179.40M$2.92B$5.36B$8.39BDividend YieldN/A1.72%5.22%4.10%P/E RatioN/A30.5126.5919.72Price / Sales14.21400.93391.61116.20Price / CashN/A168.6838.2534.62Price / Book3.103.286.794.51Net Income-$8.19M-$72.17M$3.23B$248.18M7 Day Performance2.88%4.32%4.03%1.14%1 Month Performance10.88%7.68%12.22%15.07%1 Year Performance-26.21%-28.08%16.76%6.59% Innate Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPHAInnate Pharma1.9734 of 5 stars$2.14+0.9%$11.00+414.0%-25.6%$179.40M$12.62M0.00220Gap UpIMNMImmunome2.6373 of 5 stars$8.01-0.6%$23.33+191.3%-38.0%$696.97M$10.94M-0.9940Gap DownRCKTRocket Pharmaceuticals4.9168 of 5 stars$6.45-0.8%$37.73+484.9%-70.0%$688.77MN/A-2.35240Positive NewsGap DownAVBPArriVent BioPharma1.0129 of 5 stars$19.35-0.1%$39.17+102.4%+6.5%$662.02MN/A-5.1340Analyst ForecastDAWNDay One Biopharmaceuticals2.9419 of 5 stars$6.48+3.7%$30.57+371.8%-58.8%$656.83M$161.92M-6.2960TRVITrevi Therapeutics3.6252 of 5 stars$6.49-0.2%$17.56+170.6%+128.6%$648.31MN/A-14.7520News CoveragePositive NewsAnalyst ForecastIMTXImmatics2.8315 of 5 stars$5.29+11.6%$17.00+221.4%-50.6%$643M$144.15M-8.02260News CoveragePositive NewsSIONSionna TherapeuticsN/A$14.51+8.0%$38.50+165.3%N/A$640.24MN/A0.0035EOLSEvolus3.5979 of 5 stars$9.90+2.1%$23.75+139.9%-25.8%$638.31M$275.46M-10.88170Gap UpVIRVir Biotechnology3.1102 of 5 stars$4.64+0.9%$32.86+608.1%-51.2%$635.90M$14.30M-1.18580REPLReplimune Group3.8329 of 5 stars$8.20+4.5%$19.43+136.9%+54.7%$631.52MN/A-2.67210News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies IMNM Alternatives RCKT Alternatives AVBP Alternatives DAWN Alternatives TRVI Alternatives IMTX Alternatives SION Alternatives EOLS Alternatives VIR Alternatives REPL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPHA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IPHA Stock Free IPHA Stock Alerts